APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Arterial Hypertension (PAH) Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Pulmonary Arterial Hypertension (PAH) Drugs Industry Growth and Trends Forecast to 2032

26 December 2025112 pages

Choose your research edition.

Industry ResearchPulmonary Arterial Hypertension (PAH) Drugs Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Arterial Hypertension (PAH) Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Pulmonary Arterial Hypertension (PAH) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Arterial Hypertension (PAH) Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Pulmonary Arterial Hypertension (PAH) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Pulmonary Arterial Hypertension (PAH) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Pulmonary Arterial Hypertension (PAH) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Arterial Hypertension (PAH) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs include Actelion Pharmaceuticals, Aires Pharmaceuticals, Arena Pharmaceuticals, AstraZeneca, Berlin Cures, Daiichi Sankyo, Eiger BioPharmaceuticals, Glaxosmithkline and Northern Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Pulmonary Arterial Hypertension (PAH) Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Pulmonary Arterial Hypertension (PAH) Drugs market size, estimates, and forecasts are presented in terms of sales volume (W Pcs) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Pulmonary Arterial Hypertension (PAH) Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Pulmonary Arterial Hypertension (PAH) Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Pulmonary Arterial Hypertension (PAH) Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Pulmonary Arterial Hypertension (PAH) Drugs Market by Company

Actelion Pharmaceuticals

Aires Pharmaceuticals

Arena Pharmaceuticals

AstraZeneca

Berlin Cures

Daiichi Sankyo

Eiger BioPharmaceuticals

Glaxosmithkline

Northern Therapeutics

Reata Pharmaceuticals

United Therapeutics

Bayer Healthcare

Pfizer

Merck

Novartis

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Type

Injectables

Inhalation

Oral Administration

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Application

Hospitals

Clinics

Other

Pulmonary Arterial Hypertension (PAH) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension (PAH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension (PAH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension (PAH) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension (PAH) Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Pulmonary Arterial Hypertension (PAH) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Injectables Table 2. Major Company of Inhalation Table 3. Major Company of Oral Administration Table 4. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2021-2026) & (US$/Pcs) Table 10. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2027-2032) & (W Pcs) Table 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2027-2032) & (US$/Pcs) Table 15. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 16. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 18. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 20. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 22. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (W Pcs) Table 24. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends Table 26. Pulmonary Arterial Hypertension (PAH) Drugs Industry Drivers Table 27. Pulmonary Arterial Hypertension (PAH) Drugs Industry Opportunities and Challenges Table 28. Pulmonary Arterial Hypertension (PAH) Drugs Industry Restraints Table 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Company (2021-2026) & (W Pcs) Table 32. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Company (2021-2026) Table 33. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Price by Company (2021-2026) & (US$/Pcs) Table 34. Global Pulmonary Arterial Hypertension (PAH) Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Pulmonary Arterial Hypertension (PAH) Drugs Major Company Production Sites and Headquarters Table 36. Global Pulmonary Arterial Hypertension (PAH) Drugs Company, Product Type & Application Table 37. Global Pulmonary Arterial Hypertension (PAH) Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Pulmonary Arterial Hypertension (PAH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2021-2026) & (W Pcs) Table 42. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 46. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2027-2032) & (W Pcs) Table 47. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2027-2032) Table 51. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 53. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2021-2026) & (US$/Pcs) Table 57. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2027-2032) & (W Pcs) Table 58. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2027-2032) & (US$/Pcs) Table 62. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 63. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 65. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 67. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 69. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (W Pcs) Table 71. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Actelion Pharmaceuticals Company Information Table 73. Actelion Pharmaceuticals Business Overview Table 74. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 75. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 76. Actelion Pharmaceuticals Recent Development Table 77. Aires Pharmaceuticals Company Information Table 78. Aires Pharmaceuticals Business Overview Table 79. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 80. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 81. Aires Pharmaceuticals Recent Development Table 82. Arena Pharmaceuticals Company Information Table 83. Arena Pharmaceuticals Business Overview Table 84. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 85. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 86. Arena Pharmaceuticals Recent Development Table 87. AstraZeneca Company Information Table 88. AstraZeneca Business Overview Table 89. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 90. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 91. AstraZeneca Recent Development Table 92. Berlin Cures Company Information Table 93. Berlin Cures Business Overview Table 94. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 95. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 96. Berlin Cures Recent Development Table 97. Daiichi Sankyo Company Information Table 98. Daiichi Sankyo Business Overview Table 99. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 100. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 101. Daiichi Sankyo Recent Development Table 102. Eiger BioPharmaceuticals Company Information Table 103. Eiger BioPharmaceuticals Business Overview Table 104. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 105. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 106. Eiger BioPharmaceuticals Recent Development Table 107. Glaxosmithkline Company Information Table 108. Glaxosmithkline Business Overview Table 109. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 110. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 111. Glaxosmithkline Recent Development Table 112. Northern Therapeutics Company Information Table 113. Northern Therapeutics Business Overview Table 114. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 115. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 116. Northern Therapeutics Recent Development Table 117. Reata Pharmaceuticals Company Information Table 118. Reata Pharmaceuticals Business Overview Table 119. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 120. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 121. Reata Pharmaceuticals Recent Development Table 122. United Therapeutics Company Information Table 123. United Therapeutics Business Overview Table 124. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 125. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 126. United Therapeutics Recent Development Table 127. Bayer Healthcare Company Information Table 128. Bayer Healthcare Business Overview Table 129. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 130. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 131. Bayer Healthcare Recent Development Table 132. Pfizer Company Information Table 133. Pfizer Business Overview Table 134. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 135. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 136. Pfizer Recent Development Table 137. Merck Company Information Table 138. Merck Business Overview Table 139. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 140. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 141. Merck Recent Development Table 142. Novartis Company Information Table 143. Novartis Business Overview Table 144. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (W Pcs), Revenue (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 145. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio Table 146. Novartis Recent Development Table 147. North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country (W Pcs): 2021 VS 2025 VS 2032 Table 148. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs) Table 149. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2021-2026) Table 150. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2027-2032) & (W Pcs) Table 151. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Country (2027-2032) Table 152. North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 154. North America Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Country (2021-2026) Table 155. North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. North America Pulmonary Arterial Hypertension (PAH) Drugs Market Share Forecast by Country (2027-2032) Table 157. Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country (W Pcs): 2021 VS 2025 VS 2032 Table 158. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs) Table 159. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2021-2026) Table 160. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2027-2032) & (W Pcs) Table 161. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Country (2027-2032) Table 162. Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 164. Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Country (2021-2026) Table 165. Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Share Forecast by Country (2027-2032) Table 167. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country (W Pcs): 2021 VS 2025 VS 2032 Table 168. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs) Table 169. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2021-2026) Table 170. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2027-2032) & (W Pcs) Table 171. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Country (2027-2032) Table 172. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 174. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Country (2021-2026) Table 175. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Share Forecast by Country (2027-2032) Table 177. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country (W Pcs): 2021 VS 2025 VS 2032 Table 178. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs) Table 179. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2021-2026) Table 180. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2027-2032) & (W Pcs) Table 181. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Country (2027-2032) Table 182. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 183. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 184. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Country (2021-2026) Table 185. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 186. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Share Forecast by Country (2027-2032) Table 187. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country (W Pcs): 2021 VS 2025 VS 2032 Table 188. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026) & (W Pcs) Table 189. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2021-2026) Table 190. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2027-2032) & (W Pcs) Table 191. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Country (2027-2032) Table 192. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 193. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 194. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Country (2021-2026) Table 195. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 196. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Share Forecast by Country (2027-2032) Table 197. Key Raw Materials Table 198. Raw Materials Key Suppliers Table 199. Pulmonary Arterial Hypertension (PAH) Drugs Distributors List Table 200. Pulmonary Arterial Hypertension (PAH) Drugs Customers List Table 201. Research Programs/Design for This Report Table 202. Authors List of This Report Table 203. Secondary Sources Table 204. Primary Sources List of Figures Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Image Figure 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (2021-2032) & (W Pcs) Figure 5. Injectables Image Figure 6. Global Injectables Sales YoY Growth (2021-2032) & (W Pcs) Figure 7. Inhalation Image Figure 8. Global Inhalation Sales YoY Growth (2021-2032) & (W Pcs) Figure 9. Oral Administration Image Figure 10. Global Oral Administration Sales YoY Growth (2021-2032) & (W Pcs) Figure 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Pulmonary Arterial Hypertension (PAH) Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospitals Image Figure 26. Global Hospitals Sales YoY Growth (2021-2032) & (W Pcs) Figure 27. Clinics Image Figure 28. Global Clinics Sales YoY Growth (2021-2032) & (W Pcs) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (W Pcs) Figure 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application 2025 VS 2032 Figure 33. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Application in 2025 Figure 34. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Application in 2025 Figure 35. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Application in 2025 Figure 39. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share in Value by Application in 2025 Figure 43. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Pcs) Figure 44. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Pcs) Figure 48. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Pcs) Figure 52. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Pcs) Figure 56. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Pcs) Figure 60. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Pulmonary Arterial Hypertension (PAH) Drugs Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Pulmonary Arterial Hypertension (PAH) Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Injectables
  • Inhalation
  • Oral Administration
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Actelion Pharmaceuticals
  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • AstraZeneca
  • Berlin Cures
  • Daiichi Sankyo
  • Eiger BioPharmaceuticals
  • Glaxosmithkline
  • Northern Therapeutics
  • Reata Pharmaceuticals
  • United Therapeutics
  • Bayer Healthcare
  • Pfizer
  • Merck
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Pulmonary Arterial Hypertension (PAH) Drugs Market by Type
  6. 1.3.1 Injectables
  7. 1.3.2 Inhalation
  8. 1.3.3 Oral Administration
  9. 1.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type
  10. 1.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends
  2. 2.2 Pulmonary Arterial Hypertension (PAH) Drugs Industry Drivers
  3. 2.3 Pulmonary Arterial Hypertension (PAH) Drugs Industry Opportunities and Challenges
  4. 2.4 Pulmonary Arterial Hypertension (PAH) Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Pulmonary Arterial Hypertension (PAH) Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Pulmonary Arterial Hypertension (PAH) Drugs Price (2021-2026)
  4. 3.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Pulmonary Arterial Hypertension (PAH) Drugs Company, Product Type & Application
  7. 3.7 Global Pulmonary Arterial Hypertension (PAH) Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pulmonary Arterial Hypertension (PAH) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pulmonary Arterial Hypertension (PAH) Drugs Tier 1, Tier 2, and Tier 3
4 Pulmonary Arterial Hypertension (PAH) Drugs Regional Status and Outlook
  1. 4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Historic Market Size by Region
  3. 4.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Pulmonary Arterial Hypertension (PAH) Drugs by Application
  1. 5.1 Pulmonary Arterial Hypertension (PAH) Drugs Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application
  6. 5.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Actelion Pharmaceuticals
  2. 6.1.1 Actelion Pharmaceuticals Company Information
  3. 6.1.2 Actelion Pharmaceuticals Business Overview
  4. 6.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  6. 6.1.5 Actelion Pharmaceuticals Recent Developments
  7. 6.2 Aires Pharmaceuticals
  8. 6.2.1 Aires Pharmaceuticals Company Information
  9. 6.2.2 Aires Pharmaceuticals Business Overview
  10. 6.2.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  12. 6.2.5 Aires Pharmaceuticals Recent Developments
  13. 6.3 Arena Pharmaceuticals
  14. 6.3.1 Arena Pharmaceuticals Company Information
  15. 6.3.2 Arena Pharmaceuticals Business Overview
  16. 6.3.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  18. 6.3.5 Arena Pharmaceuticals Recent Developments
  19. 6.4 AstraZeneca
  20. 6.4.1 AstraZeneca Company Information
  21. 6.4.2 AstraZeneca Business Overview
  22. 6.4.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  24. 6.4.5 AstraZeneca Recent Developments
  25. 6.5 Berlin Cures
  26. 6.5.1 Berlin Cures Company Information
  27. 6.5.2 Berlin Cures Business Overview
  28. 6.5.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  30. 6.5.5 Berlin Cures Recent Developments
  31. 6.6 Daiichi Sankyo
  32. 6.6.1 Daiichi Sankyo Company Information
  33. 6.6.2 Daiichi Sankyo Business Overview
  34. 6.6.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  36. 6.6.5 Daiichi Sankyo Recent Developments
  37. 6.7 Eiger BioPharmaceuticals
  38. 6.7.1 Eiger BioPharmaceuticals Company Information
  39. 6.7.2 Eiger BioPharmaceuticals Business Overview
  40. 6.7.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  42. 6.7.5 Eiger BioPharmaceuticals Recent Developments
  43. 6.8 Glaxosmithkline
  44. 6.8.1 Glaxosmithkline Company Information
  45. 6.8.2 Glaxosmithkline Business Overview
  46. 6.8.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  48. 6.8.5 Glaxosmithkline Recent Developments
  49. 6.9 Northern Therapeutics
  50. 6.9.1 Northern Therapeutics Company Information
  51. 6.9.2 Northern Therapeutics Business Overview
  52. 6.9.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  54. 6.9.5 Northern Therapeutics Recent Developments
  55. 6.10 Reata Pharmaceuticals
  56. 6.10.1 Reata Pharmaceuticals Company Information
  57. 6.10.2 Reata Pharmaceuticals Business Overview
  58. 6.10.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  60. 6.10.5 Reata Pharmaceuticals Recent Developments
  61. 6.11 United Therapeutics
  62. 6.11.1 United Therapeutics Company Information
  63. 6.11.2 United Therapeutics Business Overview
  64. 6.11.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  66. 6.11.5 United Therapeutics Recent Developments
  67. 6.12 Bayer Healthcare
  68. 6.12.1 Bayer Healthcare Company Information
  69. 6.12.2 Bayer Healthcare Business Overview
  70. 6.12.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  72. 6.12.5 Bayer Healthcare Recent Developments
  73. 6.13 Pfizer
  74. 6.13.1 Pfizer Company Information
  75. 6.13.2 Pfizer Business Overview
  76. 6.13.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  78. 6.13.5 Pfizer Recent Developments
  79. 6.14 Merck
  80. 6.14.1 Merck Company Information
  81. 6.14.2 Merck Business Overview
  82. 6.14.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  84. 6.14.5 Merck Recent Developments
  85. 6.15 Novartis
  86. 6.15.1 Novartis Company Information
  87. 6.15.2 Novartis Business Overview
  88. 6.15.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Portfolio
  90. 6.15.5 Novartis Recent Developments
7 North America by Country
  1. 7.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
  2. 7.1.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
  6. 7.2.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
  2. 8.1.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
  6. 8.2.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
  2. 10.1.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
  6. 10.2.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Pulmonary Arterial Hypertension (PAH) Drugs Value Chain Analysis
  2. 12.1.1 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Pulmonary Arterial Hypertension (PAH) Drugs Production Mode & Process
  7. 12.2 Pulmonary Arterial Hypertension (PAH) Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors
  10. 12.2.3 Pulmonary Arterial Hypertension (PAH) Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst